SUMO inhibition reveals temporally distinct intron retention programs shaping the immunopeptidome in acute myeloid leukemia
This study demonstrates that inhibiting SUMOylation in acute myeloid leukemia triggers temporally distinct intron retention programs that generate a diverse repertoire of novel, recurrent intron-derived antigens, thereby reshaping the immunopeptidome and identifying potential targets for therapeutic evaluation.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human immune system acts as a constant surveillance network, patrolling the body to distinguish between healthy cells and dangerous invaders. To do this, it relies on tiny molecular flags displayed on the surface of every cell. These flags, known as human leukocyte antigens, are fragments of proteins that the cell has recently broken down. If a cell is healthy, the flags show normal, expected pieces. If a cell is infected by a virus or has become cancerous, the flags display strange, foreign fragments that alert the immune system to launch an attack. In acute myeloid leukemia, a type of blood cancer, the cells often hide from this surveillance because they carry very few mutations that would create these recognizable foreign flags. This lack of visible targets makes the disease difficult to treat with immunotherapies, which depend on the immune system spotting and destroying the cancer.
Scientists have long suspected that cancer cells might display other types of hidden flags, not just those from mutated genes, but from errors in how they read their own genetic instructions. Cells must copy their DNA into RNA and then translate that RNA into proteins, a process that involves cutting out non-coding sections called introns. Sometimes, this editing process fails, and an intron is left inside the final message. This error usually leads to a broken protein that is quickly destroyed, but the fragments of these broken proteins can still end up on the cell surface as flags. The question remained whether these accidental, intron-derived flags could be made more visible to the immune system, potentially turning a hidden cancer into a target.
A team of researchers at the University of Montreal set out to test this idea by manipulating a specific chemical switch inside leukemia cells. They used a drug called TAK-981, which blocks a process known as SUMOylation. This process is like a molecular glue that helps organize the machinery inside the cell nucleus, including the tools responsible for editing RNA. By removing this glue, the researchers hypothesized that the editing machinery would become disorganized, causing more introns to be left in the genetic messages. They predicted that this surge in errors would generate a flood of new, abnormal protein fragments, effectively forcing the cancer cells to display a new set of flags that the immune system could recognize.
To see if this worked, the scientists treated three different types of leukemia cells with the drug and watched what happened over time. They found that the drug did indeed disrupt the cell's internal organization, triggering a broad stress response that included the activation of immune-signaling pathways. More importantly, the drug caused the cells to retain thousands of introns that they would normally have removed. The researchers observed that these introns did not all appear at once; instead, they accumulated in two distinct waves. One group of introns appeared quickly but in smaller numbers, while a much larger group built up slowly over the course of two days. These two groups had different physical characteristics, suggesting that the drug affected different parts of the editing machinery in different ways.
The most significant discovery was what happened to the flags on the cell surface. The researchers collected the protein fragments displayed by the cells and analyzed them with high-precision mass spectrometry. They identified nearly seventeen thousand unique flags. Among these, they found hundreds of new flags that had never been seen before in these cells. A large portion of these new flags came directly from the introns that the drug had caused to be retained. In fact, nearly sixty percent of the new flags that appeared after treatment were derived from these intronic errors. The team confirmed that these were not just random noise; they found specific sequences where a single retained intron generated multiple different flags, depending on how the cell's machinery processed the error.
To ensure these findings were not just an artifact of the laboratory, the researchers looked at the same genetic errors in untreated leukemia samples from patients. They found that the specific introns that the drug caused to accumulate were already present in the patients' cancer cells, though at lower levels. This indicated that the drug was not creating entirely new problems but was amplifying errors that were already part of the disease. When they compared these errors to healthy blood cells, they found that many of these intron-retention events were specific to the leukemia, meaning they were unlikely to be found in healthy tissue. This is a crucial detail, as it suggests that targeting these errors would not harm the patient's normal cells.
The study also revealed that these intron-derived flags were not limited to a single type of leukemia or a specific genetic mutation. They appeared across different subtypes of the disease and in cells with different genetic backgrounds. Furthermore, the researchers identified dozens of previously unknown tiny proteins, which they called microproteins, that were produced from these retained introns. Some of these microproteins generated multiple flags, and the specific flags displayed depended on the genetic makeup of the patient's immune system. This means that a single error in the genetic editing process could provide a variety of targets for different patients, increasing the chances that an immunotherapy could be tailored to an individual.
The researchers concluded that blocking the SUMOylation process is a powerful way to remodel the surface of leukemia cells, exposing a hidden layer of antigens that the immune system can potentially attack. While the study did not test whether this approach would cure the disease in patients, it established a clear biological mechanism: disrupting a specific cellular process can force cancer cells to reveal their true nature by displaying a rich array of abnormal flags. The findings suggest that combining this drug with other treatments, such as vaccines or immune therapies designed to recognize these specific intron-derived flags, could offer a new strategy for treating acute myeloid leukemia. The work opens a door to understanding how the errors inside a cancer cell can be turned into its greatest weakness.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.